Oxidative study of patients with total body irradiation: effects of amifostine treatment.
In patients undergoing bone marrow transplant (BMT), reactive oxygen species (ROS) are released as a consequence of the events related to the preparative regimen. Total body irradiation (TBI), which is known to generate ROS, is a routine preconditioning procedure prior to BMT. Several studies have demonstrated that amifostine protects normal tissues. In the present report, we investigated the oxidative state of plasma and erythrocytes in 21 patients with hematological malignancies undergoing TBI. The dose fraction was 160 cGy, twice daily (eight sessions). For ROS detection, we used electron spin resonance spectroscopy and spin-trapping technique. In all, 15 patients received amifostine prior to the irradiation and six did not. No free radical signal was detected in the plasma samples spectrum of 15 amifostine-treated patients, and five of six samples of nontreated patients showed ROS signal. Only two of 15 treated patients had mucositis degree higher than 2, whereas five of six nontreated patients suffered this complication. The average hospitalization days in treated and nontreated patients were 23.5 and 29.7, respectively. This work represents an original observation; we found by direct measurements of free radicals that ROS are released during TBI, and confirmed the amifostine radical scavenger activity.
Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Cátedra de Física y LANAIS-RLBM, Buenos Aires, Argentina. gfacorro@ffyb.uba.ar
G
G
Facorro
M M
MM
Sarrasague
H
H
Torti
A
A
Hager
J S
JS
Avalos
M
M
Foncuberta
G
G
Kusminsky
D000293:Adolescent; D000328:Adult; D004999:Amifostine / Q000494:pharmacology*; D000975:Antioxidants / Q000378:metabolism; D016026:Bone Marrow Transplantation; D002648:Child; D004912:Erythrocytes / Q000378:metabolism / Q000528:radiation effects; D005260:Female; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000378:metabolism / Q000528:radiation effects*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014916:Whole-Body Irradiation / Q000009:adverse effects*
D000975:Antioxidants; D011837:Radiation-Protective Agents; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D004999:Amifostine